# Alios BioPharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/alios-biopharma

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.aliosbiopharma.com
- Total disclosed funding: $52M
- Latest round: Series B (May 19, 2014)
- Investors on record: 5

## About

Alios BioPharma Inc. is a biopharmaceutical company focused on developing innovative therapeutics for serious viral infections. Their work aims to advance treatment options and improve patient outcomes globally.Alios BioPharma Inc., founded in 2006 and headquartered in San Francisco, US, specializes in virology therapeutics. In September 2014, the company was acquired by Johnson & Johnson for USD 1.75 billion, marking a significant strategic expansion by the parent company. The acquisition aimed to bolster Johnson & Johnson's portfolio in the field of infectious diseases. The firm has engaged in six deals since its inception, with the most recent deal occurring on September 30, 2014.Alios BioPharma Inc. develops therapies primarily targeting serious viral infections, contributing to the healthcare sector by providing advanced medical solutions. Their products are designed to meet the urgent needs of healthcare providers and patients, focusing on enhancing treatment effectiveness and patient care in various healthcare settings, including hospitals and clinics globally.Alios BioPharma's revenue is generated through its innovative therapeutic solutions aimed at addressing viral infections, with a strong focus on partnerships with healthcare organizations. Their financial model involves collaborations with healthcare providers and direct sales strategies tailored to various market segments.The recent acquisition by Johnson & Johnson highlights a commitment to leveraging Alios BioPharma's expertise in virology. The company aims to expand its product offerings into new therapeutic areas and markets, utilizing the resources from the USD 1.75 billion acquisition to fuel research and development initiatives. Strategic plans include exploring additional international markets and enhancing treatment technologies in the coming years.

## Funding rounds

- Series B, May 19, 2014, $41M — Novartis Venture Fund, SR One, Novo Holdings, Roche Venture Fund
- Series A, Jun 11, 2009, $2.6M — SR One, GlaxoSmithKline
- Series A, Jan 20, 2009, $8.4M — Novartis Venture Fund, Novo Holdings, Roche Venture Fund

## Investors

- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series A, Series B
- Novo Holdings — Series A, Series B
- Roche Venture Fund (https://capitalatlas.ai/funds/roche-venture-fund) — Series A, Series B
- SR One (https://capitalatlas.ai/funds/sr-one) — Series A, Series B
- GlaxoSmithKline — Series A